Clinical data
Trade names Urecholine
AHFS/ Monograph
MedlinePlus a682849
  • US: C (Risk not ruled out)
Routes of
Oral, subcutaneous
ATC code N07AB02 (WHO)
Synonyms 2-[(aminocarbonyl)oxy]- N,N,N-trimethyl- 1-propanaminium
CAS Number 674-38-4 YesY
PubChem (CID) 2370
DrugBank DB01019 YesY
ChemSpider 2280 YesY
UNII 004F72P8F4 YesY
KEGG C06850 YesY
Chemical and physical data
Formula C7H17N2O2
Molar mass 161.221 g/mol
3D model (Jmol) Interactive image

Bethanechol is a parasympathomimetic choline carbamate that selectively stimulates muscarinic receptors without any effect on nicotinic receptors. Unlike acetylcholine, bethanechol is not hydrolyzed by cholinesterase and will therefore have a long duration of action. Bethanechol is sold under the brand names Duvoid (Roberts), Myotonachol (Glenwood), Urecholine (Merck Frosst) and Urocarb (Hamilton).


Bethanechol alleviates dry mouth[1] and is sometimes given orally or subcutaneously to treat urinary retention resulting from general anesthetic, diabetic neuropathy of the bladder, or a side effect of antidepressants; or to treat gastrointestinal lack of muscular tone. The muscarinic receptors in the bladder and gastrointestinal tract stimulate contraction of the bladder and expulsion of urine, and increased gastrointestinal motility, respectively. Bethanechol should be used to treat these disorders only after mechanical obstruction is ruled out as a possible cause.

Its potential benefit in the treatment of cerebral palsy has been investigated.[2] Bethanechol is a powerful cholinergic agent which does not cross the blood - brain barrier and may have powerful nootropic properties in enhancement of neural signaling and processing speed as well.

Atropine is given preoperatively to prevent voiding of the bowel/bladder during surgery, Bethanechol is then given postoperatively to revert this action.[3]


Use of bethanechol, as well as all other muscarinic receptor agonists, is contraindicated in patients with asthma, coronary insufficiency, peptic ulcers, intestinal obstruction and hyperthyroidism. The parasympathomimetic action of this drug will exacerbate the symptoms of these disorders.

See also


  1. Gorsky, Meir; Epstein, Joel B.; Parry, Jamie; Epstein, Matthew S.; Le, Nhu D.; Silverman, Sol (2004-02-01). "The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy". Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 97 (2): 190–195. doi:10.1016/S107921040300564X. ISSN 1079-2104. PMID 14970777.
  2. Carter WJ (September 2008). "Unexpected benefits of bethanechol in adults with cerebral palsy". Med. J. Aust. 189 (5): 293. PMID 18759732.
  3. Obied, Hassan (2011). Cholinergic Pharmacology. CSU.

(Benavides-Haro et al. (2003)). The cholinomimetic agent bethanechol activates IK(ACh) in feline atrial myocytes. Naunyn-Schmiedederg's Arch Pharmacol. 368:309-315

This article is issued from Wikipedia - version of the 11/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.